Anterix vs SurgePays
ATEX and SURG side by side, both in telephone communications. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ATEX and SURG compare
Anterix is the larger company, worth 205 times as much as SurgePays ($1.5B against $7.4M).
Anterix keeps more of each dollar of sales as profit, with a net margin of 933% compared with −47.9% at SurgePays.
Anterix scores higher on the StockData Score (12 against 1 for SurgePays), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ATEX | SURG |
|---|---|---|
| Size and price | ||
| Market cap | $1.5B | $7.4M |
| Share price | $76.74 | $0.139 |
| Change, 1 year | 268% | −93.1% |
| Change, 5 years | 27.8% | −94.3% |
| Beta (5Y) | 0.97 | 2.49 |
| Employees | 64 | 30 |
| StockData Score | ||
| Total score | 12 (better) | 1 |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 (better) | 0 |
| Performance score | 4 (better) | 0 |
| Health score | 6 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 21.9× | – |
| P/S | 214× | 0.1× (better) |
| P/B | 5.3× | – |
| EV/EBITDA | 19.4× | – |
| P/FCF | 142× | – |
| FCF yield | 0.71% | – |
| Fair value | $44.17 | – |
| Margin of safety | −73.8% | – |
| Growth | ||
| Revenue growth (TTM) | 18.9% | – |
| Revenue growth, 5Y average | 47.8% (better) | 0.92% |
| Net income growth (TTM) | 124% | – |
| EPS growth (TTM) | 123% | – |
| Profitability | ||
| Gross margin | – | −19.6% |
| Operating margin | 1011% (better) | −41.0% |
| Net margin | 933% (better) | −47.9% |
| FCF margin | 151% | – |
| Return on equity | 27.9% | – |
| Return on invested capital | 40.7% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −15.3× |
| Current ratio | 4.85 (better) | 0.19 |
| Altman Z-score | 4.19 (better) | −21.51 |
| Piotroski F-score | 6 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 97.4% | 4.4% |
| Held by insiders | 39.3% | 9.2% |
| Insider net buying, 12 months | −$36.0M | $83.0K (better) |
| Short interest, % of float | 14.0% | 9.1% |
Go deeper
- ATEX stock overview
- ATEX income statement
- ATEX valuation and score
- SURG stock overview
- SURG income statement
- SURG valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.